Illumina, Emedgene Launch AI-Based Rare Disease Interpretation Partnership
Illumina, Emedgene Launch AI-Based Rare Disease Interpretation Partnership Illumina has launched a nonexclusive partnership with Emedgene, an artificial intelligence-based precision medicine company, to integrate automated interpretation of rare genetic disease data into Illumina’s TruSight™ Software Suite. Through the collaboration, whose value has not been disclosed, TruSight will include Emedgene’s clinical rare disease application, one of a portfolio of artificial intelligence (AI)-po...
Marcos Gonzales Einat Metzer Trusight Software Suite Software Suite Basespace Sequence Hub Sight Software Suite
Source: genengnews.com